Grace Therapeutics (GRCE) Interest Expenses (2017 - 2026)
Grace Therapeutics (GRCE) posted Interest Expenses of $2.6 million for Q1 2026, up 120.48% sequentially from $1.2 million in Q4 2025, and up 10575.0% YoY from N/an in Q1 2025.
Grace Therapeutics (GRCE) Interest Expenses (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Interest Expenses for 9 years, with the latest figure at $2.6 million in Q1 2026.
- Quarterly Interest Expenses rose 10575.0% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (up 10575.0% YoY) and the FY2026 annual result came in at $52.8 million, up 6.69% from the prior year.
- Interest Expenses rose to $2.6 million in Q1 2026 per GRCE's latest filing, from $1.2 million in the prior quarter.
- Over five years, Interest Expenses peaked at $42.4 million in Q1 2022 and troughed at $1000.0 in Q3 2023.
- A 5-year average of $3.8 million and a median of $294000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses surged 49203.49% in 2022, then tumbled 99.78% in 2023.
- Over 5 years, Interest Expenses stood at $42.4 million in 2022, then sank by 99.94% to $24000.0 in 2023, then surged by 3504.17% to $865000.0 in 2024, then soared by 34.34% to $1.2 million in 2025, then soared by 120.48% to $2.6 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $2.6 million, $1.2 million, and $600000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 93.62 Mn |
| 10 | Grace Therapeutics | 37.82 Mn | 37.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88,000.00 |
| Jun 30, 2026 | 88,000.00 |
| Mar 31, 2026 | 2.56 Mn |
| Mar 31, 2026 | 2.56 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 600,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Dec 31, 2024 | 865,000.00 |
| Dec 31, 2024 | 865,000.00 |
| Sep 30, 2024 | 294,000.00 |
| Sep 30, 2024 | 294,000.00 |
| Mar 31, 2024 | 56,000.00 |
| Mar 31, 2024 | 56,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Dec 31, 2023 | 24,000.00 |